Targeting HER2(+) breast cancer: the TBK1/IKKε axis

HER2(+) breast cancer (BC) is a highly aggressive subtype, affecting ~20% of BC patients. Current treatments include adjuvant or neoadjuvant chemotherapy plus anti-HER2 agents such as trastuzumab, a monoclonal antibody directed against HER2. Despite improvement in disease free survival, most patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhe, Liu, Jeff C., Chung, Philip E.D., Egan, Sean E., Zacksenhaus, Eldad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278282/
https://www.ncbi.nlm.nih.gov/pubmed/25594009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278282/
https://www.ncbi.nlm.nih.gov/pubmed/25594009

Ejemplares similares